Navigation Links
Group in Medical Technology

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

... the mean percent change in the Forteo(R) group for lumbar spine BMD was 5.5 percent, and for ... months compared with 8.6 percent in the Forteo(R) group and boosted femoral neck BMD by 4.1 percent ... patients enter long-term care, and half of this group never returns to living independently. ...

Labopharm files New Drug Submission with Health Canada for novel antidepressant

... baseline to the end of the study in the trazodone group versus the placebo group. Statistical ... showed statistical significance in favor of the group administered Labopharm's trazodone. In addition, ... The drop out rate was 21 percent in the placebo group and 30 percent in the trazodone group. In the ...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

... August 4 /PRNewswire/ -- Debiopharm group (Debiopharm), a Swiss-based global ... and physical inactivity. About Debiopharm group Debiopharm group is a Swiss-based global ...

Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin

... risk of breast cancer." Estrogens are a group of hormones that play a key role in regulating ... found no obvious skin benefits in this particular group of women, another study that looked at women who ... did not wait to start treatment like the other group -- did experience noticeable improvements in ...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

... respond to at least one biologic treatment, the group treated with R788 (fostamatinib disodium) did not ... ACR 70 and DAS28 response rates than the placebo group at three months, and therefore, the trial failed ... to placebo. Although the ACR scores for the R788 group were within the expected range in this patient ...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

... a Swiss-based global biopharmaceutical group of companies with a focus on the development of ... returned to normal. About Debiopharm group Debiopharm group is a Swiss-based global ...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

... a Swiss-based global biopharmaceutical group of companies with a focus on the development of ... returned to normal. About Debiopharm group Debiopharm group is a Swiss-based global ...

New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed

... levels decreased from baseline in the nevirapine group 0.2 mg/dL and increased 28.1 mg/dL in the ATV/r group (p <0.0001). Mean increases in LDL cholesterol were 15 mg/dL in the nevirapine group and 10.5 mg/dL in the ...

Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial

... Seattle, WA (a subsidiary of the Transcu group Limited, a company listed on the Singapore ... statistically lower VAS scores for the Active group as compared to the Placebo group. In addition, more than 80% of the Active group reported pain elimination and willingness to ...

Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story

... Oncology Group, an NCI-sponsored cooperative group headquartered at the University of Michigan . ... Control and Prevention for the Southwest Oncology group and director of the University of ... John Crowley, Ph.D., of the Southwest Oncology group Statistical Center and Charles A. Coltman, M.D., ...

Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet

... and medically significant conditions in the group vaccinated with Cervarix (R) were similar to the ... who received at least one vaccine dose. This group comprised a diverse population of women including ... is a registered trademark of the GlaxoSmithKline group of companies. Cautionary statement ...

Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237

... $7.5m Milestones for Both Companies Sosei group Corporation ("Sosei"; TSE Mothers Index: 4565) ... agreement with Novartis Sosei and Vectura group plc concluded a global development ... new products. About Sosei Sosei group is a leading international biopharmaceutical ...

Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative

... A Commonwealth Fund case study notes that group Health Cooperative is structured with ... Hill in cooperative structures, pointing to group Health as a "shining example" of the model, while ... create better health care, medical systems like group Health that have pioneered a different approach, ...

Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries

... a Swiss-based global biopharmaceutical group of companies with a focus on the development of ... also fewer side effects. About Debiopharm group Debiopharm group is a Swiss-based global ...

HCPC Calls for Greater Healthcare Savings Through Improved Adherence to Prescription Drug Regimens

... in two different types of packaging: one group received their drugs in standard pharmacy vials, while the other group was given the exact same drug in a unit dose ... both groups, OSU researchers found that the group who received their drugs in blister packs with ...

Scottsdale Facility to Be First in U.S. to Showcase True REST Technology

... sober and drug-free. None of the control group did so for eight months of follow-up. ... 22 percent of the participants in the floating group were entirely pain-free, and 56 percent ... session, monthly, twice a month or weekly rates. group rates are available upon request. Reservations ...

Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)

... patients of the placebo group, 55.3% of the 120 U group and 46.0% of the 240 U group. AEs reported most ... of the placebo group, in 58.1% of the 120 U group and in 71.0% of the 240 U group. AEs reported ... is the wholly owned, US subsidiary of the Merz group of Companies. A specialty pharmaceutical company, ...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

... design (e.g., endpoints, sample size, control group and statistical analyses) is acceptable to ... with only 5 patient (8%) deaths in the orBec(R) group compared to 16 patient (24%) deaths in the placebo group (p-value 0.0139). At one year post randomization ...

Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting

... in the BTXCo group, and 22.7% in the placebo group reported an adverse event. There were no ... (1.6%) were randomized to the 50 U/mL dilution group (95 patients) or to the 20 U/mL dilution group (97 patients). Limb position (60.4%), Dressing ...

Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients

... challenge was significantly lower in the TI+G group (37 vs. 54 mg/dL; p<0.0001). TI+G produced ... with AFRESA than with RAA. Patients in the AFRESA group lost weight (-0.5 +/- 0.3), while patients in the RAA group gained weight (+1.4 +/- 0.3), with the difference ...

New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar

... a multicenter, randomized, open-label, parallel group study in insulin naive patients. Lantus(R) was ... achieving A1C<7% at week 24 was greater in the group receiving Apidra(R) three times daily (45.1%) versus the group receiving Apidra(R) one time daily (29.7%, ...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

... a significantly greater extent in the lorcaserin group than the placebo group at Week 52. "We are pleased to present the ... 5% of baseline body weight in the active-product group is at least 35%, is approximately double the ...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

... statistically significantly better in the patient group randomized to Avandia after the average of 5.5 ... rates of CHF in RECORD were higher in the group randomized to Avandia (61 events or 2.7 percent ... bone fractures, which were higher in the group randomized to Avandia and were seen mostly in the ...

Top Medical Research Centers Form Velos Advisory Group for Service-Oriented Architecture

... instrumental in establishing a Velos Advisory group for Service-Oriented Architecture (SOA). Five ... and UT Southwestern Medical Center. The Advisory group will collaborate with Velos to create an SOA ... "We are pleased at the formation of this Advisory group and gratified to see institutions of such high ...

PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference

... 70-point response was 61 percent in the 500 mg QD group versus 47 percent for placebo (p=0.039). ... to 100-point response was 55 percent in this group versus 40 percent for placebo (p=0.029). In his ... of Severity (CDEIS) was observed in the 500 mg QD group compared to placebo (CDEIS decrease of -8.4 vs. ...

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

... + placebo were as follows: group SD > 12 ... with results as follows: group Median Overall Survival* % ... in the perifosine + capecitabine patient group is ongoing with 10 of the 20 patients in ...

Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables

... 60 days, 3% of patients in the relaxin-30 group had been rehospitalized for heart failure and no ... causes, as compared to 17% in the placebo group (p=0.06), a greater than 80% reduction. After an ... months, no patients in the relaxin-30 group had died of cardiovascular causes, as compared to ...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

... capecitabine + placebo were as follows: group N CR PR ORR SD > 12 ... with results as follows: group Median Overall Survival* ... in the perifosine + capecitabine patient group is ongoing with 10 of the 20 patients in this arm ...

New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer

... and Zoloft(R) (sertraline), and are among a group of drugs known as CYP2D6 inhibitors. ... but was not limited to antidepressants, and a group of 945 women on tamoxifen who were not taking any ... the cohorts using a CYP2D6 inhibitor and the group on tamoxifen only. The study found that women ...

Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer

... -- The Spanish Head and Neck Cancer Cooperative group (TTCC) announced today that Induction ... die from the disease. Head and neck cancer is a group of tumors that mostly arise in the cells that ... is a Spanish non-profit scientific cooperative group fully devoted to head and neck cancer. ...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

... agent perifosine was as follows: group N PR SD > 12 wks CBR* ... agent perifosine was as follows: group N PR SD > 12 wks CBR ... (11.7, 33.6)] Three patients out of the group of patients previously treated with and failed ...

Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

... for high-risk neuroblastoma: Children's Oncology group (COG) study ANBL0032 Lead investigator: A. L. Yu, Children's Oncology group Abstract 10067z, Oral Presentation, ... current assumptions and forecasts made by Bayer group management. Various known and unknown risks, ...

Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013

... in Europe , according to Millennium Research group WALTHAM, Mass., May 28 /PRNewswire/ -- ... and many more. About Millennium Research group Millennium Research group ( www.MRG.net ), a Decision Resources, Inc. ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... Sandostatin LAR versus 7.2 months in the placebo group (P<0.0001)(1). The trial, called PROMID ( ... enrolled in the independent Breast International group (BIG) 1-98 study (Femara(R) [letrozole tablets] ... Results from this study revealed that the group of patients receiving Femara had clinically and ...

Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia

... (median change 0.3 kg for overall lurasidone group vs. 0 kg for placebo) as was its effect on lipid ... (6% and 2% for the overall lurasidone group and placebo, respectively). Adverse events ... six-week study duration for each lurasidone dose group vs. placebo. A key secondary endpoint was the ...

First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology

... of the Genting Group. Over the years, the Asiatic group had embarked on several significant acquisitions ... in line with its long term strategy, the Asiatic group had, in June 2005, further expanded its ... to develop some 98,300 hectares. The Asiatic group also owns 5 oil mills with a total milling ...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

... decrease in FVC at week 72 in the pirfenidone group than in the placebo group. This magnitude of ... In addition, 40% more patients in the pirfenidone group did not experience a decline in percent predicted ... the ATS meeting data on the low-dose pirfenidone group for the efficacy outcome measures of change in ...

RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder

... months for patients in the RISPERDAL(R) CONSTA(R) group and five months for patients in the placebo ... among patients in the RISPERDAL(R) CONSTA(R) group (30 percent; 42/140) compared with the placebo group (56 percent; 76/135). The median dose of ...

Mutant Genes in High-Risk Childhood Leukemias Identified

... Research Hospital, the Children's Oncology group (COG), the University of New Mexico Cancer ... for a cure. The problem is that this high-risk group is likely a heterogeneous mixture of biologic ... COG, an international clinical trial cooperative group supported by the NCI. Other authors of the ...

Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms

... Problem Subscale of the NYPRS-S in the INTUNIV group compared to placebo (-16.0 vs -9.6; P< .001). ... interactions. On the PSI/SF scale, the INTUNIV group reduced its score by 17.0 compared to 7.7 for the placebo group ( P= .002). "These data are testament to ...
Other Contents
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
(Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
(Date:7/29/2015)... ... ... According to The Spirits Business on July 16th, a new study ... perpetuating alcohol use disorders. Humans have the same gene, which is called Rsu1. The ... and has given researchers inklings to explore Rsu1 in humans to abate alcohol addiction ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... anticipating testing regulations imposed by the FDA for nicotine laced liquid products. Their ... electronic cigarettes have raised considerably. E-Cigarettes are particularly troublesome to addiction professionals as ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... Michigan, changed its name in July to Kalamazoo Strength & Conditioning. , The ... , and “reflects the evolution of our training center over the past three ...
(Date:7/29/2015)... , ... July 29, 2015 , ... San Fernando ... on Ultherapy. For a limited time only, patients can get the complete treatment process ... for patients who prefer a non-invasive treatment and have loose or sagging skin. ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... For the ... to be featured in the list of the 50 fastest growing companies in Jacksonville. ... around the business community. On July 16th, a team of Vast Bridges staffers were ...
Breaking Medicine News(10 mins):Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2Health News:Vast Bridges Continues Its Swift Growth 2
Other TagsOther Tags